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Abstract
Overexpression of Her2/ErbB2/Neu in cancer is often correlated with recurrent distant metastasis, although the mechanism
still remains largely elusive. We have previously shown that EGFR, when tyrosine-phosphorylated, binds to GEP100/BRAG2
to activate Arf6, which induces cancer invasion and metastasis. We now show that overexpressed Her2 in lung
adenocarcinoma cells also employs GEP100. Like EGFR-GEP100 binding, this association is primarily mediated by the
pleckstrin homology (PH) domain of GEP100 and Tyr1139/Tyr1196 of Her2. Tyr1139/Tyr1196 are autonomously
phosphorylated, when Her2 is overexpressed. Accordingly, invasive activities mediated by the Her2-GEP100 pathway are
not dependent on external factors. Blocking Her2-GEP100 binding, as well as its signaling pathway all inhibit cancer invasive
activities. Moreover, our clinical study indicates that co-overexpression of Her2 with GEP100 in primary lung
adenocarcinomas of patients is correlated with the presence of their node-metastasis with a statistical significance. Since
the GEP100 PH domain interacts with both Her2 and EGFR, targeting this domain may provide novel cancer therapeutics.
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Introduction
The major cause of cancer-related death is the dissemination
and distant metastasis of cancer cells. Overexpression of Her2/
ErbB2/Neu, a member of the epidermal growth factor receptor
(EGFR)-family tyrosine kinases, in malignant tumors is often
correlated with recurrent distant metastasis [1,2]. Cancer cells
which overexpress Her2 generally exhibit highly migratory and
invasive properties in vitro and in vivo [3,4]. On the other hand,
Her2 expression in cancer cells is inversely correlated with cancer-
induced angiogenesis [5]. Therefore, overexpression of Her2 and
its intracellular signaling appear to be directly related to the
invasive and metastatic activities of cancer cells themselves. No
direct ligand for Her2 per se has been identified, and overexpres-
sion of Her2 induces its homo-dimer/oligomer formation and its
tyrosine phosphorylation, independent of ligand binding or
oncogenic mutations [6]. Furthermore, Her2 expressed at
moderate levels can be activated and tyrosine phosphorylated by
heterodimerization with other EGFR-family receptors and
stimulatation by their cognate ligands [7].
A small GTPase, Arf6, primarily regulates the recycling of
plasma membrane components and plays pleiotropic roles [8,9].
We have shown previously that Arf6 activity greatly contributes to
the invasive and metastatic activities of breast cancer cells, when
Arf6 is activated by GEP100/BRAG2 [10] and employs AMAP1/
DDEF1/ASAP1 as a downstream factor [11,12,13]. EGF receptor
(EGFR) is frequently overexpressed in many types of cancers,
including breast cancer and lung cancer, and is highly implicated
in their malignancy [14]. We have shown that EGFR, when
activated by its ligand, recruits GEP100 and induces the invasion
and metastasis of breast cancer cells [13]. Pathological analyses
revealed that components of the EGFR-GEP100-Arf6-AMAP1
pathway are highly expressed in 40–80% of primary tumors of the
human breast [12,13]. We have recently indentified that this
pathway acts to enhance the recycling of b1 integrin in order to
enhance cancer cell invasive activities (Onodera et al., submitted).
Besides breast cancers, melanomas also utilize Arf6 activity for
their invasion and metastasis [15].
GEP100 contains an incomplete IQ-motif, a pleckstrin
homology (PH) domain and a Sec7 domain, which encodes
guanine nucleotide exchanging factor (GEF) activity [10]. The PH
domain was originally identified as a binding module to
phophoinositides [16], while cognate ligands for most PH domains
are still unidentified [17]. The PH domain of GEP100 does not
show a notable specificity towards phophoinositides, and GEF
activity of GEP100 was not stimulated by certain phophoinositides
[8]. We have shown that this PH domain binds directly to
phosphorylated Tyr1068 and Tyr1086 of EGFR [13]. It is hence
important to clarify whether the GEP100 PH domain also binds to
other tyrosine phosphorylated proteins to induce cancer invasion.
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and lethal compared with other major epithelial tumors in clinical
settings [18]. Her2 overexpression is detected in 15–40% of
primary lung cancers [19,20,21], and correlates with the poor
prognosis of the patients [22]. Randomized controlled trials using
a humanized anti-Her2 monoclonal antibody, Trastuzumab, for
patients with Her2-overexpressing lung cancers showed no
significant survival benefits [23], contrary to the expectations
from the preclinical studies [24]. Therefore, although possible
mechanisms by which overexpressed Her2 induces cell migration
and invasion have already been extensively studied [25,4], further
elucidation of Her2-mediated invasive/metastatic mechanisms in
lung cancer are necessary for the future development of
therapeutics for this disease. Non-small cell lung cancer is the
most common subdivision of primary lung cancer, and is classified
into several categories depending on the origin of the tumor, such
as adenocarcinoma, squamous cell carcinoma and large cell
carcinoma. Here, we show that Her2 overexpressed in lung
adenocarcinoma cells employs GEP100 to activate the Arf6
pathway and induces their autonomous, stroma-independent
invasive activities. Pathological analyses indicate that overexpres-
sion of both GEP100 and Her2 in lung adenocarcinoma
specimens at the primary sites is statistically correlated with the
presence of their node-metastasis. Such an autonomous invasive/
metastatic property of Her2/GEP100-overexpressing lung can-
cers, as well as frequent existence of their node-metastasis already
at the time of surgery, appears to be a part of the reason as to why
Trastuzumab does not exhibit clear survival benefits in patients
with this disease.
Materials and Methods
Ethics statement
This study was approved by the Kyoto University Hospital
Institutional Review Board, and the written informed consent was
obtained from all patients.
Complementary DNAs. cDNAs for GEP100, ARNO, and
Her2 were described previously [13]. cDNA fragments each
encoding the PH domain of GEP100 (631–742 amino acids) or
ARNO (261–387 amino acids) were ligated into pGEX4T-2 to be in-
frame to the COOH terminus of the GST-TK-tag, and expressed in
E.coli, as described previously [13]. For mammalian expression, each
cDNA was ligated into pEGFP (for the EGFP-tag), pcDNA3 HA (for
the HA-tag), or pcDNA-myc (for the myc-tag). The YF mutants of
Her2 were generated by the PCR-based mutagenesis method, in
which tyrosines 1139, 1196, 1221, 1222 and 1248 were changed into
phenylalanine, singly or in combination.
Accession numbers. Human GEP100, AB018306; human
ARNO, X99753; human Her2, NM_004448; human AMAP1,
NM_018482; and human Arf6, NM_001663.
Chemicals and antibodies. AG825 and EGF were
purchased from Calbiochem and Sigma-Aldrich, respectively.
Rabbit polyclonal antibody against GEP100 was as described
previously [13]. Other antibodies were purchased from
commercial sources: mouse monoclonal antibodies against
hemaggultinin (HA)-tag (Babco), GFP-tag (Babco), Arf6 (Santa
Cruz), AMAP1/ASAP1 (BD Biosciences), b-actin (Sigma), EGFR
(TDL), Her2 (Neomarker), and Her3 (Neomarker); rabbit
polyclonal antibodies against HA-tag (Babco), GFP-tag (Abcam),
and Her2 (DAKO, for immunohistochemistry); rabbit monoclonal
antibody against phospho-Her2 (Y1221/1222) (Cell Signaling).
Donkey antibodies against rabbit and mouse IgGs, conjugated
with horseradish peroxidase, were from Jackson ImmunoResearch
Laboratories.
Cells. 293T cells obtained from American Type Culture
Collection were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% FCS (Hyclone). Human non-small cell lung
cancer cell lines were obtained from and authenticated by
American Type Culture Collection and RIKEN (Lu99, PC9 and
PC14), and were cultured in RPMI-1640 medium with 10% FCS.
All above cell lines were used in our experiments within 15
passages.
Transfection. cDNA transfections were performed by using
Lipofectamine 2000 (Invitrogen) for H522 cells; and Polyfect
(Qiagen) for 293T cells, according to the manufacturer’s
instructions. Transfected cells were incubated for 24 h with
growth medium or in a starved condition before being subjected
to analyses.
RNA interferrence was performed with 25 nM of duplex
oligonucleotides using Lipofectamine 2000 (Invitrogen) and
incubated for 48 h before being subjected to analyses. Oligonu-
cleotides were synthesized by Japan BioServices (Saitama, Japan).
Sequences used were as follows. GEP100: 59-GTGAAAT-
CACTGGCCGAGT-39, Arf6: 59-GCACCGCATTATCAAT-
GACCG-39, and AMAP1: 59-GACCTGACAAAAGCCATTA-
39. The control irrelevant siRNA was 59-GCGCGCTTTGTAG-
GATTCG-39. Upon siRNA treatment, cell viability was measured
using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) assay, and ratios of the
viability between the treated cells and the control are shown.
Glutathione S-transferase (GST)–golgi-localized, c-ear-
containing, Arf-binding protein (GGA) pulldown,
immunoprecipitation and immunoblotting
Arf6 activities were measured using GST-GGA, as previously
described [26], by using 500 mg of cell lysates in each assay.
Shortly, cells were transfected with Arf6-myc, HA-GEP100, and
Her2-GFP, and the cells were incubated for 24 hours in serum-
free DME medium. Cells were lysed in GGA3-buffer (50 mM
Tris-HCl (pH 8.0), 100 mM NaCl, 10 mM MgCl2, 0.005% SDS,
0.05% sodium deoxycholate, 1% Triton X-100, 10% glycerol with
1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, and 5 mg/
ml aprotinin). Each lysate was precleared by centrifugation after
the incubation for 30 minutes with the glutathione magnetic beads
(Thermo Scientific). Then, 500 ug of each clarified lysate was
incubated with 20 ug of GST-GGA3 bound to glutathione
magnetic beads at 4uC for 40 min. The beads were then washed
three times with GGA3-buffer. Bound proteins were eluted into
SDS-PAGE sample buffer. These samples were measured for the
presence of Arf6 by Western blotting with the antibody against
myc-tag. Total levels of Arf6-myc, HA-GEP100, and Her2-GFP
were assayed by Western blotting of 20 ug of the precleared lysate.
For coprecipitation assays of GEP100 with Her2, cells were
lysed in GGA3 buffer. 300 mg of cell lysates were then incubated
with an anti-GEP100 polyclonal antibody, coupled to Protein G-
magnetic beads (Millipore).
For in vitro protein binding assays, 25 mg of GST-fused PH
domain, expressed in bacteria and purified on glutathione-beads,
were incubated with 200 mg of cell lysates prepared in GGA3
buffer at 4uC for 1 h, and proteins co-precipitated with the beads
were analysed by immunoblots, as described previously [13].
Immunoblotting analysis, coupled with SDS-PAGE, was
performed as described previously [13].
Matrigel invasion. Matrigel chemoinvasion assay was
performed with Biocoat Matrigel chambers (BD Biosciences), as
described previously [11], in which 1610
5 cells were seeded on the
upper wells. No chemoattractants or serum was added in the
chambers. After incubation for 24 h, cells were fixed and stained
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25301Figure 1. GEP100 associates with Her2 to induce Arf6 activation. (A) Co-precipitation of Her2-EGFP with HA-GEP100, expressed in 293T cells,
and analysed by anti-GEP100 immunoprecipitation (IP) coupled with anti-GFP immunoblots (IB). Anti-GEP100 immunoprecipitants were also blotted
by anti-phospho Her2 and an anti-HA antibody. Immunoprecipitation for the expression of Her2-EGFP without HA-GEP100 was included as a control
(vector). Immunoprecipitation using non-immune serum was also included as a control (NC). (B) In vitro co-precipitation of Her2-EGFP (pEGFP-Her2)
expressed in cells with the two indicated GST-tagged PH domains (GST-GEP100-PH/GST-ARNO-PH) or GST alone, analysed by glutathione-beads
pulldown and anti-GFP immunoblots. GST-fusion proteins were visualized by Ponceau S. In A and B, cells were cultured with 10% FCS (Se), in the
absence of serum for 24 h (St), or stimulated with 10 ng/ml EGF for 10 min after serum starvation for 24 h (E), prior to lysis. EGFP alone was included
as a control (pEGFP). (C) Co-precipitation of HA-GEP100 with wild type Her2-EGFP (WT) or its mutants (YF1; 1139F, YF2; 1196F, YF3; 1221/1222F, YF4;
1248F, YF1/2; 1139/1196F, YF3/4; 1221/1222/1248F), analysed by anti-GEP100 immunoprecipitation and anti-GFP immunoblots. (D) Arf6-myc
activities in cells expressing HA-GEP100 and Her2-EGFP or their mutants, measured by GST-GGA pulldown and anti-myc immunoblots. +, wild type;
YF, Her2 1139/1196F mutant; Del, Sec7-deleted GEP100. EGFP alone was included as a control (G). In A–D, immunoblots of total cell lysates (10 mg)
are also shown (Total).
doi:10.1371/journal.pone.0025301.g001
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migrated-out to the lower surface of the membranes were scored.
Data were collected from three independent experiments, each
done in duplicate.
Pathology. All clinical specimens were from patients with
primary lung adenocarcinomas, who underwent pulmonary
resection at Kyoto University Hospital between May 2001 and
September 2004. This study was approved by the Kyoto
University Hospital Institutional Review Board, and the written
informed consent was obtained from all patients. Pathological
stage was evaluated according to the 6th version of international
tumor, node, metastasis (TNM) staging system and the
classification of the World Health Organization (WHO). Patients
with pathological stage 3B or 4 were unexpectedly recognized
during or after the surgical operation, or during the palliative
surgery. Patient data were obtained from inpatient and outpatient
medical records.
Immunohistochemical staining was performed on 4 mm-thick
formalin-fixed paraffin-embedded sequential sections. Immuno-
histochemical staining against GEP100 or Her2 was performed by
using the standard avidin-biotin-peroxidase complex (ABC)
method, as described [12]. Each section was counterstained with
hematoxylin. Two investigators independently scored the maximal
intensity of tumors (HER2; 0,3+, GEP100; 0,2+).
Statistical analyses. Continuous variables in each
experitment were analysed with ANOVA or Kruskal-Wallis test,
and nominal variables were analysed with Fisher’s exact test by
using the statistics software, Graphpad Prism. The caluculated p-
value was considered to be significant when less than 0.05.
Results
Binding of GEP100 with Her2
Our previous analyses showed that GEP100 does not form a
complex with Her2, which is expressed at a moderate level in
MDA-MB-231 breast cancer cells [13]. Her2 is frequently
overexpressed in many malignant cancers. We here examined
whether overexpressed Her2 binds to GEP100. For this, we first
expressed Her2, tagged with enhanced green fluorescence protein
(EGFP) at the C-terminus, together with hemagultinnin (HA)-
tagged GEP100 in 293T cells by cDNA transfection. Pull-down of
HA-GEP100 using an anti-GEP100 antibody efficiently copreci-
pitated Her2-EGFP (Fig. 1A). Under these conditions, Her2-
EGFP was heavily tyrosine phosphorylated, and this phosphory-
lation was not affected by the presence or absence of serum, nor by
the addition of EGF (Fig. 1A). Binding of HA-GEP100 with Her2-
EGFP was also unaffected by serum or EGF (Fig. 1A and B). We
then performed an in vitro binding assay using affinity-purified
glutathione-s-transferase (GST)-tagged GEP100 PH domain, and
found that this domain alone binds to Her2-EGFP (Fig. 1B). As a
control, we found that GST-tagged ARNO PH domain does not
bind to Her2-EGFP (Fig. 1B).
We have shown previously that the GEP100 PH domain binds
to phosphotyrosines [13]. Her2 overexpression induces autophos-
phorylation of its five major tyrosines, namely Tyr1139, Tyr1196,
Tyr1221, Tyr1222 and Tyr1248 [14]. We then mutated these
tyrosines into phenylalanines. We first found that none of the
single mutations of Tyr1139 (1139F), Tyr1196 (1196F) and
Tyr1248 (1248F) nor a double mutation of Tyr1221/1222
(1221/1222F) affect Her2 binding to GEP100 (Fig. 1C). However,
we then found that simultaneous mutation of Tyr1139 and
Tyr1196 (1139/1196F) abolished Her2 binding to GEP100 almost
completely, while simultaneous mutation of Tyr1221, Tyr1222
and Tyr1248 (1221/1222/1248F) did not (Fig. 1C). These results
suggest that Tyr1139 and Tyr1196 are each independently
involved in GEP100 binding, similar to what we have observed
in the case of EGFR binding to GEP100 [13]. The N-terminal
sequences of Tyr1139 and Tyr1196 resemble each other, namely
PQPEpY for Tyr1139 and ENPEpY for Tyr1196.
We then expressed Her2-EGFP or its mutants together with
HA-GEP100 and Arf6-myc in 293T cells, and measured
activation of Arf6-myc by use of the GST-GGA pulldown method
[26]. We found that coexpression of Her2-EGFP with HA-
GEP100 induces Arf6 activation, while coexpression of GFP with
HA-GEP100 or coexpression of the YF1/2 mutant of Her2-EGFP
with HA-GEP100 did not (Fig. 1D). No exogenous ligands were
added in these experiments. Together with the results described
above, these results collectively indicate that overexpressed Her2
physically associates with GEP100 to activate Arf6, which is
primarily mediated by Tyr1139/1196 of Her2 and the PH domain
of GEP100.
Figure 2. Endogenous binding of GEP100 with Her2 overex-
pressed in H522 lung adenocarcinoma cells. (A) Total lysates
(30 mg) of 11 non-small cell lung cancer cell lines were immunoblotted
with antibodies as indicated. (B) Co-precipitation of Her2 with GEP100
from H522 cell lysates (250 mg), analysed by anti-GEP100 immunopre-
cipitation, and the immunoblot for anti-GEP100, anti-Her2 (HER2), and
anti-phospho Her2 (pHER2). Immunoblots using anti-EGFR (EGFR) and
anti-Her3 (HER3) antibodies were also included. Cells were cultured in
the presence of serum (Se), or starved for serum for 24 h (St), prior to
lysis. Total, 20 mg of total lysates. Immunoprecipitation of cells using
non-immune serum was used as a negative control (NC).
doi:10.1371/journal.pone.0025301.g002
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PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e25301Figure 3. Inhibition of the Her2-GEP100 pathway blocks invasive activities of H522 cells. (A) Cells, untreated or treated with AG825
(10 mM) or DMSO (1%) for 72 h, were subjected to the Matrigel invasion assay, or their lysates (30 mg) were analysed by immunoblotting as indicated.
Cell viability, measured by the MTS assay, is also shown. (B) Cells, untransfected (mock), or transfected with siRNA duplexes against GEP100 or
irrelevant sequences (Irr), were subjected to the Matrigel invasion assay and the MTS assay; or were analysed for their expression of GEP100 by
immunoblotting of the lysates (20 mg) using the antibody as indicated. b-actin immunoblots were included as controls. (C) Cells, expressing EGFP-
tagged GEP100 PH domain (EGFP-GEP100-PH) or EGFP alone (EGFP), were subjected to the Matrigel invasion assay and the MTS assay. Inhibition of
the intracellular association of GEP100 with Her2 by EGFP-GEP100-PH, as well as the association of EGFP-GEP100-PH with endogenous Her2, were
confirmed by anti-GEP100 and anti-GFP immunoprecipitation coupled with anti-Her2 immunoblot, as indicated. IP, immunoprecipitant for total cell
lysates (250 mg). Total, total cell lysates (30 mg). (D) Cells, untransfected (mock) or transfected with siRNA duplexes against Arf6, AMAP1, or with
irrelevant sequences (Irr), were subjected to the Matrigel invasion assay and the MTS assay; or were analysed for their expression of Arf6 and AMAP1
by immunoblotting of the lysates using the antibodies as indicated. b-actin immunoblots were included as controls. In each bar chart, data of invasive
activities (black columns) and cell viabilities (white columns) are presented as percentages calculated by normalizing the values obtained for the
untreated cells (3A) which means native cells, or the mock cells (3B, 3C, and 3D) to which only transfection reagents were added as 1.0. Error bars
show mean +/2 s.e.m., n=3. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0025301.g003
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We next searched for non-small cell lung cancer cell lines that
exclusively overexpress Her2. From the eleven human lung cancer
cell lines we examined, including adenocarcinoma (Ad), squamous
cell carcinoma (Sq) and large cell carcinoma (La), we found that
H522 cells express Her2 at a very high level, while this cell line
expresses only a small amount of Her3 and no detectable amount
of EGFR (Fig. 2A). We found that Her2 is coprecipitated with an
anti-GEP100 antibody and heavily tyrosine phosphorylated in
H522 cell lysates, even when the cells are cultured in the absence
of ligands or serum (Fig. 2B). H522 cells were derived from a lung
adenocarcinoma. Mutations within the kinase domain of Her2
have been reported to occur in 1–10% of human lung
adenocarcinomas [27,28]. We however found no mutation within
the Her2 kinase domain in H522 cells (data not shown).
Inhibition of the Her2-GEP100 pathway blocks cancer
invasion
H522 cells have been shown to be invasive as assessed by the
Matrigel invasion assay [29]. We first confirmed that treatment of
H522 cells with AG825, an inhibitor of Her2 kinase activity,
blocks their Matrigel invasion activity (Fig. 3A). Note that,
however, AG825 even at 10 mM could only partially inhibit the
kinase activity of Her2 in H522 cells, as assessed by the
phosphorylation of Tyr1221/1222 (Fig. 3A), and inhibited
Matrigel invasion activity only by about 60% (Fig. 3A). We next
tested the effects of GEP100 knockdown. We tested several
different sequences of GEP100 siRNAs, but all of them were not
very effective in inhibiting protein expression of GEP100 in H522
cells (Fig. 3B). Under these conditions, GEP100 siRNAs inhibited
their Matrigel invasion activity by about 40% (Fig. 3B). We then
overexpressed the GFP-tagged GEP100 PH domain to block the
endogenous binding of Her2 with GEP100. Although blockage by
the GFP-GEP100 PH domain was not complete under this
condition (Fig. 3C), the Matrigel invasion activity of H522 cells
was inhibited by 50% (Fig. 3C). Matrigel invasion activities of
H522 cells were unaffected by 0.1–10 ng/ml EGF (data not
shown), and we did not add chemoattractants or serum
throughout these Matrigel invasion assays.
We also sought to obtain evidence that Arf6 as well as its
effector, AMAP1, are involved in the invasion activity of H522
cells. We found that Ar6 and AMAP1 siRNAs are effective in
suppressing these protein expression in H522 cells (Fig. 3D), and
the Matrigel invasion activity is inhibited by 50% and 70%,
respectively (Fig. 3D). Note that unlike GEP100 siRNAs, AMAP1
siRNAs notably affected cell viability (Fig. 3D). Treatment of cells
with Arf6 siRNA affected the viability of H522 cells more
seriously, and we could not properly assess the invasion activity.
High levels of GEP100 expression in Her2-overexpressing
lung adenocarcinomas is correlated with node-
metastasis
Adenocarcinoma is the major histological subtype of lung
cancer, and rates of Her2 overexpression are significantly higher in
adenocarcinomas than other histological types of lung cancer [30].
One hundred and thirty two specimens of lung adenocarcinoma
were immunostained for Her2 and GEP100. Their maximum
intensities was scored by two independent investigators (T.M. and
Y.T.), in which scores were 0,3+ for Her2 and 0,2+ for
GEP100. Table 1 shows characteristics of the patients, and Table 2
shows distribution of the scores. Representative staining images
are shown in Fig. 4A. We used the same antibody against Her2 as
used in the Herceptest (DAKO, A0485). Our results of Her2
staining were consistent with a previous report [31], in which the
population of specimens scored 2+ and 3+ were approximately
40%. Among the 132 specimens, about 50% of them were strongly
positive for GEP100 (score 2+). Notably, GEP100 expression
within each cancer was heterogeneous, while Her2 expression was
rather homogeneous (Fig. 4B). On the other hand, sites of
maximum intensity of GEP100 staining were located mostly at
peripheral areas of the cancer mass (Fig. 4B), consistent with a
notion that invasion is primarily initiated by cells located at the
periphery.
Throughout these specimens, strong expression of GEP100
(score 2+) per se was not correlated with node-positive status
(metastatic, 19/38 (50.0%) vs. non-metastatic, 49/94 (52.1%);
p=0.8496) (Fig. 4C). However, in the node-positive cases with
Her2-overexpression (score 3+), all of them also overexpressed
GEP100 (score 2+). On the other hand, in the node-positive cases
with lower Her2 expression (score 0,2+), less than 50%
overexpressed GEP100 (Her2 score 3+ & GEP100 score 2+, 6/6
(100.0%) vs. Her2 score 0,2+ & GEP100 score 2+, 13/32
(40.6%); p=0.0197) (Fig. 4D). In the node-negative cases,
GEP100 expression was not correlated with their Her2 status
(Fig. 4D). Therefore, strong co-expression of GEP100 and Her2 in
lung adenocarcinomas at the primary sites is significantly
correlated with presence of their node-metastases.
Discussion
Her2 overexpression is a major risk factor for various types of
cancer [5,32,33]. Intracellular signaling pathways of Her2 have
been extensively studied, and Her2 may promote invasive and
metastatic activities through Ras- and Rho-family small GTPases
[34,35], PI3K/Akt pathway [36], MMP [25], and also miR21
Table 1. Patient profiles.
Sex M/F 63/69
Age 31–83 (mean 66)
Smoking current/ex/never 41/27/64
Differentiation well/moderately/poorly 59/54/19
T-factor T1/T2/T3/T4 82/34/7/9
N-factor N0/N1/N2/N3 94/15/22/1
p-stage 1A/1B/2A/2B/3A/3B/4 67/22/5/6/21/7/4
doi:10.1371/journal.pone.0025301.t001
Table 2. Summary of immunohistochemical analyses of
surgical specimens of human lung adenocarcinoma.
HER2
01 + 2+ 3+ Total
G E P 1 0 00 1 7 9503 1( 2 3 . 5 % )
1+ 8 1 5 553 3( 2 5 % )
2+ 72 32 31 56 8 ( 5 1 . 5 % )
Total 32 47 33 20 132
(59.8%) (40.2%)
The expression pattern of Her2 and GEP100 in 132 samples of lung
adenocarcinoma were determined and summarized.
doi:10.1371/journal.pone.0025301.t002
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small GTPase, Arf6, via its association with GEP100, and induces
cancer cell invasion. Our results indicate that simultaneous
overexpression of GEP100 and Her2 in primary lung adenocar-
cinomas is statistically correlated with the presence of node-
metastases. We hence propose that overexpression of both
GEP100 and Her2 provides a biomarker predictive for the distant
metastases of lung adenocarcinomas.
GEP100 expression was heterogeneous even within a single
lesion of lung adenocarcinoma, while Her2 showed more
homogeneous expression. On the other hand, GEP100 expression
was predominantly observed at peripheries of the cancer mass.
Therefore, expression of GEP100 in cancer cells does not seem to
be a primary result of genome alterations that caused the cells to
become cancerous, but may be inducible even in malignant cancer
cells. Therefore, identification of factors and conditions that affect
GEP100 protein expression, within cancer cells and the microen-
vironment, will be important for understanding the mechanism
that determines whether lung adenocarcinoma cells become
invasive and metastatic.
Resistance against or inefficacy of Trastuzumab, used as a single
agent, occurs frequently in breast cancer and lung cancer [38,39].
One explanation for this would be the incomplete inhibition of
overexpressed Her2 by Trastuzumab, which may then cause
lateral activation of residual Her2 molecules through their
heterodimerization with other EGFR-family members [40]. The
GEP100 PH domain binds both to EGFR and Her2. Moreover,
engagement of GEP100 with these growth factor receptor tyrosine
Figure 4. Immunohistochemistry of Her2 and GEP100 in adenocarcinoma lung tissue specimens. (A) Her2 and GEP100 were each
stained in brown in sequential sections. Case 1, Her2 and GEP100 double negative; Case 2, Her2 score 1+ and GEP100 score 1+; Case 3, Her2 score 2+
and GEP100 score 2+; Case 4, Her2 score 3+ GEP100 and GEP100 score 2+. All sections were counterstained with hematoxylin and eosin (H&E) and
representative figures are shown. Scale bars, 100 mm. (B) Representative figures of the peripheral expression of GEP100. Scale bars, 500 mm. (C)N o
correlation between strong expression of GEP100 (score 2+) per se with node-metastases. (D) A statistical correlation between double strong positive
signal of GEP100 (score 2+) and Her2 (score 3+), and node-metastases. In C and D, solid bars mean GEP100 positive rate for strong expression (score
2+).
doi:10.1371/journal.pone.0025301.g004
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during specific cellular conditions such as movement [13].
Therefore, targeting this PH domain appears to be highly
advantageous, not only since it inhibits both Her2 and EGFR
signaling for invasion, but since it may exhibit little side effects on
cellular mechanisms other than migration. Small inhibitors
targeting this domain might also be effective when used in
combination with Trastuzumab, perhaps by compensating for the
inefficacy of Trastuzumab-based therapy.
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